COMPANY PROFILE // THE 014 REPORT
Editas Medicine, Inc.
EDIT (Nasdaq)
Assembled from 5 government sources in 0.2 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber8-K Item 4.01 filed: change in the company's certifying accountant (auditor) on 2026-04-07 (last 24 months).
- AmberLEI 5299000AON4Q9NT2JE42 registration status is LAPSED (last update 2021-07-13): the legal-entity record has not been renewed.
- InfoGLEIF: no direct parent reported; reporting exception reason NON_CONSOLIDATING.
- InfoUSAspending recipient TKSATEM5TEK6 (matched to this company by exact name) has no entity registration in the SAM.gov public extract of 2026-11-01.possible match
✓ SEC filings✓ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
Editas Medicine, Inc. is an SEC-registered operating company in biological products, (no diagnostic substances), incorporated in DE, based in Cambridge, MA; listed as EDIT (Nasdaq).[source] It reported revenue of $40.5 million for the fiscal year ended 2025-12-31.[source] It has filed 68 documents with the SEC in the last 12 months; the latest is Form 4, filed 2026-11-13.[source] Its largest institutional holders on 13F filings are TCG Crossover Management, LLC, BlackRock, Inc., ADAR1 Capital Management, LLC (as of 2026-06-30).[source] Seraphix flags 2 items from these records: 8-K Item 4.01 filed; LEI 5299000AON4Q9NT2JE42 registration status is LAPSED (last update 2021-07-13).[source]
- red0
- amber2
- info2
- TCG Crossover Management, LLC$36.0M
- BlackRock, Inc.$34.3M
- ADAR1 Capital Management, LLC$28.8M
- Commodore Capital LP$28.8M
- RA CAPITAL MANAGEMENT, L.P.$28.8M
- VANGUARD CAPITAL MANAGEMENT LLC$19.9M
- Paradigm Biocapital Advisors LP$18.1M
- Opaleye Management Inc.$12.5M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Editas Medicine, Inc., is a clinical-stage biotechnology company that is developing therapies for rare diseases using CRISPR gene editing technology. Editas Medicine headquarters is located in Cambridge, Massachusetts with additional facilities in Boulder, Colorado. (Wikipedia, CC BY-SA 4.0)
Officers and directors (Forms 3, 4, 5)
- Burkly Linda · EVP, CHIEF SCIENTIFIC OFFICER (Officer) · latest Form 4 2026-03-16 · filing · LinkedIn search
- O'Neill Gilmore Neil · CEO (Director,Officer) · latest Form 4 2026-03-16 · filing · LinkedIn search
- Parison Amy · SVP, Chief Financial Officer (Officer) · latest Form 4 2026-03-16 · filing · LinkedIn search
- Connaughton Bernadette · Director · latest Form 4 2025-06-10 · filing · LinkedIn search
- Hirsch Andrew · Director · latest Form 4 2025-06-10 · filing · LinkedIn search
- Hopfield Jessica · Director · latest Form 4 2025-06-10 · filing · LinkedIn search
- Levy Elliott M. · Director · latest Form 4 2025-06-10 · filing · LinkedIn search
- Scadden David · Director · latest Form 4 2025-06-10 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Wilmer Cutler Pickering Hale and Dorr LLP · Exhibit 5.1 legal opinion, S-3 filed 2026-08-31
Links
- Official website (Wikidata or the SEC record)
- Wikipedia
- Wikidata
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 25 CLEAR, 1 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001650664 | source |
| LEI | 5299000AON4Q9NT2JE42 | source |
| UEIpossible match | TKSATEM5TEK6 | source |
| EIN | 46-4097528 | source |
| Business address (SEC) | 11 HURLEY ST., CAMBRIDGE, MA, 02141 | source |
Does not exist in the records we hold: NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2019-10-10 · in -2,600 days · LEI next renewal (5299000AON4Q9NT2JE42)
- 2027-03-31 · in 129 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 174 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2836 (biological products, (no diagnostic substances)): 183 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- AMGEN INC · 123 SEC filings in 12 months · 1 flag · $507.4M federal (possible match)
- Vir Biotechnology, Inc. · 117 SEC filings in 12 months · 1 flag · $65.9M federal (possible match)
- Vericel Corp · 109 SEC filings in 12 months · 1 flag · $37.3M federal (possible match)
- Coherus Oncology, Inc. · 53 SEC filings in 12 months · 3 flags · $11.8M federal (possible match)
- BIO-TECHNE Corp · 77 SEC filings in 12 months · 1 flag · $6.6M federal (possible match)
- Twist Bioscience Corp · 337 SEC filings in 12 months · 2 flags · $5.9M federal (possible match)
- Adaptive Biotechnologies Corp · 185 SEC filings in 12 months · 1 flag · $1.9M federal (possible match)
- AGENUS INC · 82 SEC filings in 12 months · 3 flags · $613K federal (possible match)
- REPLIGEN CORP · 89 SEC filings in 12 months · 1 flag · $457K federal (possible match)
- Revolution Medicines, Inc. · 171 SEC filings in 12 months · 2 flags · $15K federal (possible match)
- RECURSION PHARMACEUTICALS, INC. · 174 SEC filings in 12 months · 1 flag
- GILEAD SCIENCES, INC. · 173 SEC filings in 12 months
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- AGIOS PHARMACEUTICALS, INC. · David Scadden, M.D.
- C4 Therapeutics, Inc. · Andrew Hirsch
- HALOZYME THERAPEUTICS, INC. · Bernadette Connaughton
- INSULET CORP · Jessica Hopfield, Ph.D.
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-09 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-09 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-10-08 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-09-09 filing S-8 · SEC EDGAR
- 2026-09-08 filing EFFECT · SEC EDGAR
- 2026-08-31 filing S-3 · SEC EDGAR
- 2026-08-31 filing 144 · SEC EDGAR
- 2026-08-31 filing 144 · SEC EDGAR
- 2026-08-05 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-05 officer change 8-K items 2.02,5.02,9.01 · SEC EDGAR
- 2026-07-21 filing 144 · SEC EDGAR
- 2026-06-18 filing 8-K items 5.07 · SEC EDGAR
- 2026-05-29 filing 144 · SEC EDGAR
- 2026-05-26 filing 424B5 · SEC EDGAR
- 2026-05-26 filing 8-K items 1.01,8.01,9.01 · SEC EDGAR
- 2026-05-26 filing S-3MEF · SEC EDGAR
- 2026-05-26 filing 8-K items 8.01 · SEC EDGAR
- 2026-05-26 filing 424B5 · SEC EDGAR
- 2026-05-26 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-05-14 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-05-05 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-05 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-28 filing ARS · SEC EDGAR
- 2026-04-28 filing DEFA14A · SEC EDGAR
- 2026-04-28 filing Proxy statement · SEC EDGAR
- 2026-04-07 filing 8-K items 4.01,9.01 · SEC EDGAR
- 2026-03-27 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-03-09 filing Annual report (10-K) · SEC EDGAR
- 2026-03-09 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-02-27 filing 144 · SEC EDGAR
155 earlier entries
- 2025-12-01 filing 144
- 2025-11-10 filing Quarterly report (10-Q)
- 2025-11-10 filing 8-K items 2.02,9.01
- 2025-10-09 filing 8-K items 7.01,8.01,9.01
- 2025-09-02 filing 8-K items 7.01,8.01,9.01
- 2025-08-29 filing 144
- 2025-08-29 filing 144
- 2025-08-12 filing Quarterly report (10-Q)
- 2025-08-12 filing 8-K items 2.02,9.01
- 2025-07-30 filing 144
- 2025-06-12 filing 8-K items 7.01,8.01,9.01
- 2025-06-10 insider First Form 3/4/5 on record for Connaughton Bernadette (Director)
- 2025-06-10 insider First Form 3/4/5 on record for Hirsch Andrew (Director)
- 2025-06-10 insider First Form 3/4/5 on record for Hopfield Jessica (Director)
- 2025-06-10 insider First Form 3/4/5 on record for Levy Elliott M. (Director)
- 2025-06-10 insider First Form 3/4/5 on record for Scadden David (Director)
- 2025-06-04 insider First Form 3/4/5 on record for Burkly Linda (EVP, CHIEF SCIENTIFIC OFFICER)
- 2025-06-04 insider First Form 3/4/5 on record for O'Neill Gilmore Neil (CEO)
- 2025-06-02 filing 144
- 2025-06-02 officer change 8-K items 5.02,5.03,5.07,9.01
- 2025-05-14 filing 8-K items 7.01,8.01,9.01
- 2025-05-13 filing 8-K items 7.01,8.01,9.01
- 2025-05-12 filing Quarterly report (10-Q)
- 2025-05-12 filing 8-K items 2.02,9.01
- 2025-04-15 filing ARS
- 2025-04-15 filing DEFA14A
- 2025-04-15 filing Proxy statement
- 2025-04-08 insider First Form 3/4/5 on record for Parison Amy (SVP, Chief Financial Officer)
- 2025-04-04 filing PRE 14A
- 2025-03-21 filing EFFECT
- 2025-03-20 officer change 8-K items 5.02
- 2025-03-05 filing POS AM
- 2025-03-05 filing S-8
- 2025-03-05 filing Annual report (10-K)
- 2025-03-05 filing 8-K items 2.02,9.01
- 2025-03-05 filing POSASR
- 2025-02-28 filing 144
- 2025-02-28 filing 144
- 2025-02-28 filing 144
- 2025-01-13 filing 8-K items 2.02,7.01,9.01
- 2024-12-17 officer change 8-K items 5.02
- 2024-12-12 officer change 8-K items 2.05,5.02,7.01,8.01,9.01
- 2024-12-10 filing 8-K items 5.03,7.01,9.01
- 2024-11-04 filing Quarterly report (10-Q)
- 2024-11-04 filing 8-K items 2.02,9.01
- 2024-10-22 filing 8-K items 2.02,7.01,9.01
- 2024-10-04 filing 8-K items 1.01,2.03,7.01,9.01
- 2024-08-29 filing 144
- 2024-08-29 filing 144
- 2024-08-07 filing Quarterly report (10-Q)
- 2024-08-07 filing 8-K items 2.02,9.01
- 2024-07-18 filing 144
- 2024-07-18 filing 144
- 2024-06-27 officer change 8-K items 5.02
- 2024-06-14 filing 8-K items 7.01,8.01,9.01
- 2024-05-31 filing 144
- 2024-05-31 filing 144
- 2024-05-31 filing 8-K items 5.07
- 2024-05-17 filing 144
- 2024-05-08 filing Quarterly report (10-Q)
- 2024-05-08 filing 8-K items 2.02,9.01
- 2024-04-16 filing DEFA14A
- 2024-04-16 filing Proxy statement
- 2024-03-04 filing 144
- 2024-02-28 filing S-3ASR
- 2024-02-28 filing S-8
- 2024-02-28 filing Annual report (10-K)
- 2024-02-28 filing 8-K items 2.02,9.01
- 2023-12-13 filing 8-K items 7.01,8.01,9.01
- 2023-12-11 filing 8-K items 7.01,8.01,9.01
- 2023-11-22 officer change 8-K items 5.02,9.01
- 2023-11-03 filing Quarterly report (10-Q)
- 2023-11-03 filing 8-K items 2.02,9.01
- 2023-10-10 officer change 8-K items 5.02
- 2023-08-02 filing Quarterly report (10-Q)
- 2023-08-02 filing 8-K items 2.02,9.01
- 2023-06-15 filing 8-K items 1.01,8.01,9.01
- 2023-06-15 filing 424B5
- 2023-06-14 filing 424B5
- 2023-06-09 filing 8-K items 7.01,8.01,9.01
- 2023-06-05 filing 8-K items 5.07
- 2023-06-02 filing 144
- 2023-05-17 officer change 8-K items 5.02
- 2023-05-11 filing 144
- 2023-05-05 filing Quarterly report (10-Q)
- 2023-05-05 filing 8-K items 2.02,9.01
- 2023-04-18 filing ARS
- 2023-04-18 filing DEFA14A
- 2023-04-18 filing Proxy statement
- 2023-04-13 officer change 8-K items 5.02
- 2023-03-14 officer change 8-K items 5.02,5.03,9.01
- 2023-02-22 filing S-8
- 2023-02-22 filing Annual report (10-K)
- 2023-02-22 filing 8-K items 2.02,9.01
- 2023-01-09 officer change 8-K items 5.02
- 2022-12-06 filing 8-K items 8.01,9.01
- 2022-11-17 filing 8-K items 8.01,9.01
- 2022-11-02 filing Quarterly report (10-Q)
- 2022-11-02 filing 8-K items 2.02,9.01
- 2022-08-03 filing Quarterly report (10-Q)
- 2022-08-03 filing 8-K items 2.02,9.01
- 2022-06-13 filing 8-K items 5.07
- 2022-05-04 filing Quarterly report (10-Q)
- 2022-05-04 filing 8-K items 2.02,9.01
- 2022-04-26 filing DEFA14A
- 2022-04-26 filing Proxy statement
- 2022-04-14 officer change 8-K items 5.02
- 2022-02-24 filing S-8
- 2022-02-24 filing Annual report (10-K)
- 2022-02-24 filing 8-K items 2.02,9.01
- 2022-02-07 officer change 8-K items 5.02
- 2021-11-09 filing Quarterly report (10-Q)
- 2021-11-08 filing 8-K items 2.02,9.01
- 2021-10-28 officer change 8-K items 5.02
- 2021-10-15 filing CT ORDER
- 2021-09-29 filing 8-K items 7.01,8.01,9.01
- 2021-09-08 officer change 8-K items 5.02
- 2021-08-05 filing Quarterly report (10-Q)
- 2021-08-04 filing 8-K items 2.02,9.01
- 2021-07-13 filing CT ORDER
- 2021-06-08 filing 8-K items 5.07
- 2021-05-21 filing DEFA14A
- 2021-05-14 filing 8-K items 1.01,9.01
- 2021-05-14 filing 424B5
- 2021-05-06 filing Quarterly report (10-Q)
- 2021-05-05 filing 8-K items 2.02,9.01
- 2021-04-20 filing DEFA14A
- 2021-04-20 filing Proxy statement
- 2021-03-23 filing SEC STAFF LETTER
- 2021-03-01 filing S-8
- 2021-03-01 filing S-3ASR
- 2021-02-26 filing Annual report (10-K)
- 2021-02-25 filing 8-K items 2.02,9.01
- 2021-02-23 filing SEC STAFF LETTER
- 2021-02-19 officer change 8-K/A items 5.02
- 2021-02-08 officer change 8-K items 5.02,9.01
- 2021-01-21 filing 8-K items 1.01,8.01,9.01
- 2021-01-21 filing 424B5
- 2021-01-19 filing 8-K items 2.02,8.01,9.01
- 2021-01-19 filing 424B5
- 2021-01-11 officer change 8-K items 5.02,8.01,9.01
- 2021-01-11 filing 424B7
- 2020-12-18 officer change 8-K items 5.02
- 2020-11-06 filing Quarterly report (10-Q)
- 2020-11-05 filing 8-K items 2.02,9.01
- 2020-08-07 filing Quarterly report (10-Q)
- 2020-08-06 filing 8-K items 1.01,1.02,2.02,9.01
- 2020-06-25 filing 8-K items 1.01,8.01,9.01
- 2020-06-25 filing 424B5
- 2020-06-23 filing S-3ASR
- 2020-06-15 filing 8-K items 5.07
- 2020-05-15 filing 424B5
- 2020-05-15 filing 8-K items 1.01,9.01
- 2020-05-08 filing Quarterly report (10-Q)
- 2020-05-07 filing 8-K items 2.02,9.01
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-09 (within 30 days) 10-Q filed
- 2026-11-09 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-08 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-09-30 (older) Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-09-09 (older) S-8 filed
- 2026-09-08 (older) EFFECT filed
- 2026-08-31 (older) S-3 filed
- 2026-08-05 (older) 10-Q filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-21; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:EDIT The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
4 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1650664 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | EDIT / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| LEI (root of the ownership tree) | 5299000AON4Q9NT2JE42 | id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 5299000AON4Q9NT2JE42) | GLEIF |
| EIN | 464097528 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001650664 | SEC EDGAR / IRS |
| CUSIP | 28106W103 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001650664 | SEC EDGAR |
possible match: matched by name only, not merged (2)
Identifiers carried by records that share the company's exact name. Not merged into the identity above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| EPA FRS id | 110070224874 (EDITAS MEDICINE INC) | name-exact:legal-name: same registered legal name as 'Editas Medicine, Inc.' | EPA ECHO facilities |
| EPA FRS id | 110070796633 (EDITAS MEDICINE INC) | name-exact:legal-name: same registered legal name as 'Editas Medicine, Inc.' | EPA ECHO facilities |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $40,520,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-21 16:57 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$160,060,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-21 16:57 UTC | Report an error |
| Total assets (at 2025-12-31) | $186,534,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-21 16:57 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $27,288,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-21 16:57 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $146,645,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-21 16:57 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 16:57 UTC | Report an error |
| SIC industry | 2836 Biological Products, (No Diagnostic Substances) | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 16:57 UTC | Report an error |
| State of incorporation | DE | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 16:57 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 16:57 UTC | Report an error |
| Business address | 11 HURLEY ST., CAMBRIDGE, MA, 02141 | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 16:57 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 16:57 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$165,241,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-21 16:57 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $607,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-21 16:57 UTC | Report an error |
| Long-term debt (at 2025-12-31) | $53,605,000 | 2025-12-31 | 10-K, XBRL LongTermDebtNoncurrent | as filed | 2026-11-21 16:57 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $18,102,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-21 16:57 UTC | Report an error |
| Form D total offering amount (D filed 2015-08-18) | $119,999,970 | 2015-08-18 | D | as filed | 2026-11-21 16:57 UTC | Report an error |
| Form D total amount sold (D filed 2015-08-18) | $119,999,970 | 2015-08-18 | D | as filed | 2026-11-21 16:57 UTC | Report an error |
| Form D industry group | Biotechnology | 2015-08-18 | D | as filed | 2026-11-21 16:57 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2015-08-18 | D | as filed | 2026-11-21 16:57 UTC | Report an error |
| Form D date of first sale | 2015-08-04 | 2015-08-18 | D | as filed | 2026-11-21 16:57 UTC | Report an error |
| Plan (pension, plan no. 001) | EDITAS MEDICINE, INC. 401(K) PLAN: 352 participants, assets $35,446,818 | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-21 16:57 UTC | Report an error |
| Plan (welfare, plan no. 501) | EDITAS MEDICINE, INC. - GROUP BENEFITS PLAN: 138 participants | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-21 16:57 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-09 · accession 0001650664-26-000103
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $10,365,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-09 | 0001650664-26-000103 | 2026-11-21 16:57 UTC | Report an error |
| Net income (loss) | -$23,393,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-09 | 0001650664-26-000103 | 2026-11-21 16:57 UTC | Report an error |
| Interest expense | $5,000,000 | 9 months ended 2026-09-30 | 10-Q | 2026-11-09 | 0001650664-26-000103 | 2026-11-21 16:57 UTC | Report an error |
| Cash and cash equivalents | $93,169,000 | at 2026-09-30 | 10-Q | 2026-11-09 | 0001650664-26-000103 | 2026-11-21 16:57 UTC | Report an error |
| Contract liabilities (total) | $36,315,000 | at 2026-09-30 | 10-Q | 2026-11-09 | 0001650664-26-000103 | 2026-11-21 16:57 UTC | Report an error |
| Contract liabilities, current | $32,315,000 | at 2026-09-30 | 10-Q | 2026-11-09 | 0001650664-26-000103 | 2026-11-21 16:57 UTC | Report an error |
| Contract liabilities, noncurrent | $4,000,000 | at 2026-09-30 | 10-Q | 2026-11-09 | 0001650664-26-000103 | 2026-11-21 16:57 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-09 Filing 10-Q filed
- 2026-11-09 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-08 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-09-30 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-09-09 Filing S-8 filed
- 2026-09-08 Filing EFFECT filed
- 2026-08-31 Filing S-3 filed
- 2026-08-05 Filing 10-Q filed
- 2026-08-05 Filing 8-K filed: Item 2.02 results of operations; Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-06-18 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-06-11 Record latest certified decision date in the file
- 2026-05-29 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 501)
- 2026-05-26 Filing 424B5 filed
- 2026-05-26 Filing 8-K filed: Item 1.01 material agreement; Item 8.01 other event; Item 9.01 exhibits
- 2026-05-26 Filing S-3MEF filed
- 2026-05-26 Filing 8-K filed: Item 8.01 other event
- 2026-05-26 Filing 424B5 filed
- 2026-05-26 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-05-14 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-05-05 Filing 10-Q filed
- 2026-05-05 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-28 Filing ARS filed
- 2026-04-28 Filing DEFA14A filed
- 2026-04-28 Filing DEF 14A filed
- 2026-04-22 Record earliest certified decision date in the file
6 earlier entries
- 2026-04-07 Filing 8-K filed: Item 4.01 auditor change; Item 9.01 exhibits
- 2026-03-27 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-03-09 Filing 10-K filed
- 2026-03-09 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2014-01-01 Record plan effective date: EDITAS MEDICINE, INC. 401(K) PLAN
- 2014-01-01 Record plan effective date: EDITAS MEDICINE, INC. - GROUP BENEFITS PLAN
8-K item text, as filed (excerpts)
- 2026-11-09 8-K Item 2.02, Results of Operations and Financial Condition
On November 9, 2026, Editas Medicine, Inc. (the “Company”) issued a press release announcing financial results for the fiscal quarter ended September 30, 2026 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly… the 8-K · retrieved 2026-11-21 16:57 UTC - 2026-10-08 8-K Item 7.01, Regulation FD Disclosure
On October 8, 2026, Editas Medicine, Inc. (the “Company”) issued a press release titled “Editas Medicine Receives Approval to Initiate First-in-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia,” a copy of which is furnished as Exhibit 99.1 hereto. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as… the 8-K · retrieved 2026-11-21 16:57 UTC - 2026-10-08 8-K Item 8.01, Other Events
On October 8, 2026, the Company announced that it has received approval to initiate the Phase 1/2 Strive™ clinical trial of EDIT-401 in patients with heterozygous familial hypercholesterolemia in Australia. The trial has received Human Research Ethics Committee approval and completed the Clinical Trial Notification process with Australia’s Therapeutic Goods Administration and has also been submitted for review in New Zealand. If approved in New Zealand, patients in both countries will be eligible to enroll in the Strive trial. EDIT-401 is an experimental, potentially best-in-class in vivo gene editing medicine for the treatment of hyperlipidemia. Utilizing Editas’ differentiated… the 8-K · retrieved 2026-11-21 16:57 UTC - 2026-08-05 8-K Item 2.02, Results of Operations and Financial Condition
On August 5, 2026, Editas Medicine, Inc. (the “Company”) issued a press release announcing financial results for the fiscal quarter ended June 30, 2026 and other business highlights. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 2.02 in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth… the 8-K · retrieved 2026-11-21 16:57 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · GROUPED BY SOURCE8. Enforcement by agency
EPA ECHO facilities (2)
possible match: matched by name only, not merged (2)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchEDITAS MEDICINE INC · exact legal name · sx:epa:110070224874 Compare
- possible matchEDITAS MEDICINE INC · exact legal name · sx:epa:110070796633 Compare
Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | TCG Crossover Management, LLC | $36,000,000 | 2026-06-30 | SEC 13F filing | 2026-11-21 16:57 UTC | Report an error |
| 2 | BlackRock, Inc. | $34,311,568 | 2026-06-30 | SEC 13F filing | 2026-11-21 16:57 UTC | Report an error |
| 3 | ADAR1 Capital Management, LLC | $28,800,360 | 2026-06-30 | SEC 13F filing | 2026-11-21 16:57 UTC | Report an error |
| 4 | Commodore Capital LP | $28,800,360 | 2026-06-30 | SEC 13F filing | 2026-11-21 16:57 UTC | Report an error |
| 5 | RA CAPITAL MANAGEMENT, L.P. | $28,800,360 | 2026-06-30 | SEC 13F filing | 2026-11-21 16:57 UTC | Report an error |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | $19,897,929 | 2026-06-30 | SEC 13F filing | 2026-11-21 16:57 UTC | Report an error |
| 7 | Paradigm Biocapital Advisors LP | $18,100,665 | 2026-06-30 | SEC 13F filing | 2026-11-21 16:57 UTC | Report an error |
| 8 | Opaleye Management Inc. | $12,512,653 | 2026-06-30 | SEC 13F filing | 2026-11-21 16:57 UTC | Report an error |
| 9 | VANGUARD PORTFOLIO MANAGEMENT LLC | $11,658,618 | 2026-06-30 | SEC 13F filing | 2026-11-21 16:57 UTC | Report an error |
| 10 | Woodline Partners LP | $11,519,810 | 2026-06-30 | SEC 13F filing | 2026-11-21 16:57 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
GLEIF OWNERSHIP TREE · ID TIER11. Subsidiaries
1 legal entity in the company's GLEIF ownership tree, joined by LEI (an official identifier).
- EDITAS MEDICINE, INC. · LEI 5299000AON4Q9NT2JE42 · root
Exhibit 21 subsidiaries: not held yet.
DOL H-1B (LCA) · WARN NOT HELD12. Labor
Unconfirmed: these labor figures (positions, worksite states, certified LCAs later withdrawn) are as read from DOL's quarterly LCA disclosure file. Seraphix's independent second check of them is not finished (11-19); they are shown as filed, not as verified.
WARN layoff notices: not held yet.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
2 state and city records carry this company's exact name, from 2 sources. Possible matches only.
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchEditas Medicine, Inc. · exact legal name · sx:ctgov:h410483328ed1fd50 Compare
USAspending (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchEDITAS MEDICINE, INC. · exact legal name · sx:usaspending:TKSATEM5TEK6 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1650664.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001650664. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.